lansoprazole has been researched along with Diabetes Mellitus, Type 2 in 5 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Global rates of obesity and type 2 diabetes mellitus (T2DM) are increasing globally concomitant with a rising prevalence of sleep deprivation and sleep disorders." | 2.72 | The links between sleep duration, obesity and type 2 diabetes mellitus. ( Antza, C; Kostopoulos, G; Mostafa, S; Nirantharakumar, K; Tahrani, A, 2021) |
| "Treatment with lansoprazole resulted in up to ninefold dose-dependent increases in endogenous gastrin levels (p < 0." | 1.36 | Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. ( Bödvarsdóttir, TB; Gotfredsen, CF; Hove, KD; Karlsen, AE; Petersen, JS; Pridal, L; Vaag, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antza, C | 1 |
| Kostopoulos, G | 1 |
| Mostafa, S | 1 |
| Nirantharakumar, K | 1 |
| Tahrani, A | 1 |
| Kao, HW | 1 |
| Tsai, KW | 1 |
| Lin, WC | 1 |
| Dik, B | 1 |
| Coşkun, D | 1 |
| Bahçivan, E | 1 |
| Üney, K | 1 |
| Takebayashi, K | 1 |
| Sakurai, S | 1 |
| Suzuki, T | 1 |
| Hori, K | 1 |
| Terasawa, T | 1 |
| Naruse, R | 1 |
| Hara, K | 1 |
| Suetsugu, M | 1 |
| Tsuchiya, T | 1 |
| Aoki, H | 1 |
| Hamasaki, T | 1 |
| Shuutou, H | 1 |
| Inukai, T | 1 |
| Bödvarsdóttir, TB | 1 |
| Hove, KD | 1 |
| Gotfredsen, CF | 1 |
| Pridal, L | 1 |
| Vaag, A | 1 |
| Karlsen, AE | 1 |
| Petersen, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes[NCT02345239] | Phase 3 | 14 participants (Anticipated) | Interventional | 2015-02-28 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for lansoprazole and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The links between sleep duration, obesity and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Lansoprazole; Life Style; Obesity; Risk Facto | 2021 |
1 trial available for lansoprazole and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Co | 2014 |
3 other studies available for lansoprazole and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Lansoprazole; Metformin; Proton Pump Inhibitors; Stomach | 2023 |
Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats
Topics: Albendazole; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glu | 2021 |
Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Animals; Blood Glucose; Diabetes Mell | 2010 |